Synvista Therapeutics Reports Results Of Three Phase 2 Clinical Trials Of SYI-2074 In Diabetic Patients With Cardiovascular Disease

 07.06.2008 13:15   medicalnewstoday.com

Synvista Therapeutics, Inc. (Amex: SYI) announced data from three Phase 2 trials (Trials 201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a established that haptoglobin (Hp) types, the target of Synvista's proprietary haptoglobin variant test currently under development, correlated with a difference in baseline levels of plasma isoprostanes, confirming that Hp2-2 in diabetic patients is associated with increased oxidized lipids.

World Cardiology